Application of a colorectal cancer ctDNA methylation test in endocrine cancers

Jean M. Winter, Lorraine Sheehan-Hennessy, Susanne Kartin Pedersen, Molla M. Wassie, Graeme P. Young , Erin L. Symonds

Research output: Contribution to journalMeeting Abstractpeer-review


Background: Assays for circulating tumor DNA (ctDNA) have shown utility for cancer detection and management. It is important to demonstrate cancer specificity of targeted ctDNA biomarkers. Detection of methylated BCAT1 and IKZF1 ctDNA has shown high sensitivity for colorectal cancer (CRC). The aim of this study was to investigate whether hypermethylation of these two biomarkers is also present in prostate or breast adenocarcinoma (PCa or BCa) tissues, and if they are detectable as ctDNA from such cancer patients.
Original languageEnglish
Number of pages2
JournalJournal of Clinical Oncology
Issue number15
Publication statusPublished - 20 May 2021


  • circulating
  • tumor
  • DNA
  • ctDNA
  • cancer
  • methylated
  • endocrine
  • prostate
  • breast
  • colonoscopy


Dive into the research topics of 'Application of a colorectal cancer ctDNA methylation test in endocrine cancers'. Together they form a unique fingerprint.

Cite this